Treatment of patients with relapsed or refractory acute myelold leukemia (AML) with recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate
作者
E.L. Slevers,Irwin D. Bernstein,Ricardo Spielberger,Stephen J. Forman,Kathleen Shannon‐Dorcy,F. R. Appelbaum